TARA

Protara Therapeutics, Inc. [TARA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TARA Stock Summary

Top 10 Correlated ETFs

TARA

Top 10 Correlated Stocks

TARA

In the News

TARA Financial details

Company Rating
-
Market Cap
34.3M
Income
-39.73M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-0.4
Forward P/E
-
PEG
0.1
P/S
-
P/B
0.36
P/C
-
P/FCF
-1.02
Quick Ratio
10.93
Current Ratio
11.49
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.51
EPS next Y
-
EPS next Q
-
EPS this Y
-38.02%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
3.45%
-
-
-
-
SMA20
-14.71%
SMA50
0.25%
SMA100
115.96%
Inst Own
-
Inst Trans
-
ROA
-77%
ROE
-76%
ROC
-0.15%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.04-5.24
52W High
-25.6%
52W Low
+272%
RSI
33.05
Rel Volume
1.18
Avg Volume
229.16K
Volume
270.34K
Perf Week
-9.27%
Perf Month
-37.79%
Perf Quarter
86.93%
Perf Half Y
73.02%
-
-
-
-
Beta
1.877
-
-
Volatility
0.19%, 0.48%
Prev Close
-5.82%
Price
3.72
Change
-6.3%

Something similar

Top by Market Cap
ABEA.DE
MSF.DE
BRYN.DE
FB2A.DE
META
Top Correlated ETFs
INCO
PIN
INDL
INDA
INDY
Top Correlated Stocks
GHM
FBIO
ITOCY
MEOH
MUX
Similar Market Cap
IIGD
WBND
REVS
WPLCX
HDGE.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 229.16K
  • Market Capitalization 34.3M
  • Employee 26
  • CEO Mr. Jesse Shefferman
  • Headquarters New York,NY,US
  • IPO Date 2014-10-22
  • Website https://www.protaratx.com

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.